2396-61-4

Basic information

• Product Name: 3,3'-oxydipropanol
• Synonyms: 3,3'-oxydipropanol;3-(3-Hydroxypropoxy)-1-propanol;3,3'-Oxybis(1-propanol);4-Oxaheptane-1,7-diol;3,3'-oxybis(propan-1-ol);1-Propanol,3,3'-oxybis-
• CAS NO: 2396-61-4
• Molecular Formula: C₆H₁₄O₃
• Molecular Weight: 134.17356
• EINECS: 219-251-4
• Mol File: 2396-61-4.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 264°Cat760mmHg
• Flash Point: 113.5°C
• Appearance: /
• Density: 1.04g/cm³
• Vapor Pressure: 2.2Pa at 50℃
• Storage Temp.: Hygroscopic, Refrigerator, under inert atmosphere
• Solubility: Chloroform
• PKA: 14.58±0.10(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: 3,3'-oxydipropanol(CAS DataBase Reference)
• NIST Chemistry Reference: 3,3'-oxydipropanol(2396-61-4)
• EPA Substance Registry System: 3,3'-oxydipropanol(2396-61-4)

Safety Data

• Hazardous Substances Data: 2396-61-4(Hazardous Substances Data)

Usage

Uses

3,3''-Oxydipropanol is an intermediate in the synthesis of 3,3''-[Oxybis(3,1-propanediyloxy)]bis[1-propanol] (O870290). 3,3''-[Oxybis(3,1-propanediyloxy)]bis[1-propanol] is derived from 3-(Benzyloxy)propyl 4-Toluenesulfonate (B288830), which is used as a reagent in the synthesis of Silodosin (S465000); an antidysuria drug. 3-(Benzyloxy)propyl 4-Toluenesulfonate is also used as a reagent in the preparation of aryloxyalkyl derivatives of adenine which have antiviral activity.

Upstream product

• 7783-06-4 hydrogen sulfide 
• 504-63-2 trimethyleneglycol 
• 7647-01-0 hydrogenchloride 
• 5465-07-6 β-hydroxyethyl-2 dioxanne-1,3 
• 17615-28-0 di-n-propyl 4-oxa-1,7-heptanedioate 
• 57-55-6 propylene glycol 
• 75-56-9 methyloxirane 
• 102275-51-4 2-<2-(2-hydroxyethoxy)ethyl>-1,3-dioxane 
• 5961-83-1 3-(2-carboxyethoxy)propionic acid 
• 1656-48-0 2-cyanoethyl ether 
• 635677-60-0 1-benzyloxy-3-(3-benzyloxy-propoxy)propane 
• 34399-67-2 1-bromo-3-(1-ethoxyethoxy)propane 
• 627-30-5 1-chloro-3-hydroxypropane 
• 17615-27-9 diethyl-4-oxa-heptanedioate 

Downstream Products

• 504-63-2 trimethyleneglycol 
• 55333-98-7 hexapropyleneglycol 
• 1549672-94-7 C₁₃H₁₉NO 
• 110-91-8 morpholine 
• 1417792-20-1 C₃₃H₃₁ClFN₃O₉S 
• 1417792-37-0 C₃₅H₃₅ClFN₃O₉S 
• 1417792-36-9 C₂₆H₂₈ClFN₂O₆ 
• 1417792-35-8 C₂₆H₂₆ClFN₂O₈ 
• 1417792-33-6 C₁₃H₁₈ClNO₆ 
• 55333-89-6 5,9,13,17,21-Pentaoxapentacosandinitril 
• 58929-41-2 [3-(4-Chloro-phenoxy)-propyl]-(3-{3-[[3-(4-chloro-phenoxy)-propyl]-(2-methoxy-ethyl)-amino]-propoxy}-propyl)-(2-methoxy-ethyl)-amine 
• 58929-37-6 [2-(2-Chloro-phenoxy)-ethyl]-(3-{3-[[2-(2-chloro-phenoxy)-ethyl]-(2-methoxy-ethyl)-amino]-propoxy}-propyl)-(2-methoxy-ethyl)-amine 
• 58929-39-8 [2-(4-Chloro-phenoxy)-ethyl]-(3-{3-[[2-(4-chloro-phenoxy)-ethyl]-(2-methoxy-ethyl)-amino]-propoxy}-propyl)-(2-methoxy-ethyl)-amine 
• 99629-66-0 bis-3-(3-tosylpropoxy)propyl 3-oxaheptanedioate 

Relevant articles and documents

3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF

The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.

AQUEOUS PIGMENT DISPERSION CONTAINING LOW MOLECULAR WEIGHT POLYTRIMETHYLENE ETHER GLYCOL

The present disclosure is directed to an aqueous pigment dispersion comprising low molecular weight polytrimethylene ether glycol. This disclosure is further directed to an antimicrobial aqueous pigment dispersion comprising the low molecular weight polytrimethylene ether glycol. The pigment dispersion can be used in coating compositions as interior and exterior top coats, basecoats, primers, primer surfacers and primer fillers. The disclosure is particularly directed to an aqueous pigment dispersion comprising components derived from renewable resources.

AZOLE DERIVATIVES AS WTN PATHWAY INHIBITORS

The present invention relates to new compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy. Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway. For example, these may be used in preventing and/or retarding proliferation of tumor cells, for example carcinomas such as colon carcinomas.